AzTrials
AzTrials

Pilonidal DiseaseNCT05830734

Injection of Freshly Collected Autologous Adipose Tissue Additional to Bascom's Cleft Lift Surgery

A study testing injection of freshly collected adipose cells and Bascoms Cleft lift procedure in people with Pilonidal Disease, run by University of Aarhus at 1 site in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

In brief, the right management of complex or recurrent pilonidal disease (PD) is still controversial. In our institution we treat these conditions with Bascom's cleft lift surgery. Though this approach for most parts is beneficial, a large proportion of patients will suffer from prolonged post operative healing. Read more about this study

Who is it for?
Ages 15 years and older
Conditions the study is for
Pilonidal Disease
What is being tested?
injection of freshly collected adipose cells and Bascoms Cleft lift procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
140 participants
Where
1 siteDenmark
Study dates
4 Jan 2023to 31 Mar 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 years and older
  • All sexes
  • No healthy volunteers
  • Child, Adult, Older adult

Who may be able to join

  • Advanced pilonidal disease with indication for surgery with Bascom's cleft lift surgery due to either
  • Primary extensive manifestation where minimally invasive surgery is not possible
  • Lack of healing after previous surgery (> 2 months)
  • Recurrence after previous elective surgery
  • Informed and written consent, as well as consent for follow-up.
  • Danish speaking/reading and thus able to understand Danish patient information, questionnaires and the pleje.net system.

Who cannot join

  • Acute infection in pilonidal disease
  • Pregnancy
  • BMI <20 and >35
  • Smokers (stop smoking at least 6 weeks before and after the operation)
  • Insulin-dependent diabetes
  • Age <15 years
  • Bilateral extension not suitable for BCL surgery

Trial locations and contacts

1 site in 1 country.

Ida Faurschou, MD contact

28707759

idafau@rm.dk

susanne Haas, MD PHD contact

31565246

susahaas@rm.dk

Denmark1 site, 1 recruiting
  • Regions Hospitalet Randers

    Randers, Jylland, 8930

    Anne Sofie Kannerup, MD PhD, 78421201, annkan@rm.dk

    susanne Haas, 31565246, susahaas@rm.dk

    Recruiting

Other trials in Denmark

About this study

Official title: Examining the Effect of Additional Injection of Freshly Collected Autologous Adipose Tissue to Bascom's Cleft Lift Surgery in the Treatment of Pilonidal Disease- a Randomized Controlled Trial

In brief, the right management of complex or recurrent pilonidal disease (PD) is still controversial. In our institution we treat these conditions with Bascom's cleft lift surgery. Though this approach for most parts is beneficial, a large proportion of patients will suffer from prolonged post operative healing. We have published some positive results on treating non-healing postoperative wounds after cleft lift surgery with autologous fatty cell transplantation. The overall aim of the project is to investigate whether the addition of autologous fat cell transplantation in the surgical treatment of PD reduces the incidence of patients with prolonged postoperative healing. In a double-blinded randomized controlled clinical trial, we will investigate the effect of injections of freshly harvested autologous fatty cells in addition to Bascom's cleft lift operation versus Bascom's cleft lift operation alone.

Read the detailed description

The overall aim of the project is to investigate whether the addition of autologous fatty cell transplantation in the surgical treatment of pilonidal disease (PD) reduces the incidence of patients with prolonged postoperative healing. In a double-blinded randomized controlled clinical trial, the investigators will investigate the effect of injections of freshly harvested autologous fatty cells in addition to Bascom's cleft lift operation versus Bascom's cleft lift operation alone.

The investigators hypothesize that addition of autologous fatty cell injection to Bascom's cleft lift operation for pilonidal disease will reduce the proportion of patients with poor postoperative healing compared to patients in the control group who are treated with Bascom's cleft lift operation alone.

The primary endpoint of this study is healing of the pilonidal lesion (max 1 defect ≤5mm, no undermining) after 4 weeks and 12 weeks.

Further, symptom development, postoperative pain, complication rate, time to healing and recurrence rates are also explored.

BRIEF LITERATURE REVIEW:

Pilonidal disease (PD) is a widespread disorder that occurs in the crena ani. A paradigm shift in our perception of the pathology causing this disorder has been coming for several decades and the treatment is slowly conforming to this.

The estimated incidence is 26-48 per 100,000, although globally there is great geographical variation (1). Men present with treatment-requiring pilonidal disease more than twice as often as women, and population studies of young students have found up to a 10:1 male/female ratio, including asymptomatic pilonidal cysts(2). In the investigators own material, the proportion of women are 17% of patients with complicated pilonidal disease (62/363). The disorder most often affects younger patients with an average age at first manifestation of 21 years for men and 19 for women (1).

Acute manifestations are infected cysts and results in the formation of pilonidal abscesses. The treatment of these is uncontroversial and is based on lateral incision and drainage with secondary open healing.

Chronic pilonidal disease manifests itself in the formation of more or less widespread subcutaneous branching systems containing hair which is "sucked" into the system by negative pressure that occurs when changing position, especially from sitting to standing. The condition is characterized by pain and foul-smelling secretions and bleeding.

The treatment of the chronic manifestations, as opposed to the acute abscesses, has been controversial and over the last 1-2 decades has gradually moved more towards lateralization techniques, the gap between the buttocks is (partially) levelled surgically and the suture line is placed outside the midline of the crena ani (3,4).

Bascom's cleft lift operation is one of several lateralization techniques that have shown promising results over the past decades (5-10). Nevertheless, in the hands of the investogators poor or delayed healing is found in up to a third of these otherwise young and healthy patients, which seems to be in line with the international literature (11). Many patients thus experience long outpatient courses postoperatively with several additional treatments such as regular surgical wound revision, treatment with various forms of negative pressure bandaging, steroid cream regimens or silvernitrate dressings.

Platelet-rich plasma therapy (BPT) is used with good effect as an addition to the surgical treatment of pilonidal disease, as BPT promotes angiogenesis, cell regeneration and thus promotes healing. A review finds a reduction in healing time of 36% in BPT-treated patients compared to the control group(12,13). Moreover, treatments with allogeneic adipose-derived stem cells are used in other healing-challenged areas, such as mb. Crohn's fistulas and burns (14-16). However, both treatments are both time-consuming and expensive, and the investigators believe that autologous fat cell transplantation is a faster and more affordable alternative, which a study in Mb. Crohn's patients with complicated peri-anal fistulas also support: Here, in a series of 21 patients healing was found in 57% (clinical and MR-verified) - a very satisfactory result in this context (17). The cell composition in the stromal vascular fraction (SVF) of the harvested adipose tissue has been found to contain 10%-50% live stromal (mesenchymal) stem cells and 7%-30% endothelial cells (mature and stem cells) depending on where the fat is harvested and which method is used (18-20). This cell composition supports the healing potential in the treatment with autologous fatty cell transplantation.

In the department of the investigators, a series of operations with autologous fatty cell injections for non-healing pilonidal wounds has been carried out with good results. Thus, in these highly selected patients, the investigators have a healing rate of 83% (69-96%) over a median time of 159 days. Two patients had recurrence (6.7%) (21).

The method is minimally invasive and is combined in this study with Bascom's cleft lift (BCL) operation. The results seem promising with minimal risks and it could be an important supplement to the basic treatment of these patients.

  1. METHOD

STUDYDESIGN:

The study will be conducted as a double-blinded randomized controlled clinical trial that will compare healing after BLC surgery with injections of freshly harvested autologous adipose tissue versus BLC surgery alone. The trial is being conducted as a multicenter study, where patients are included at two centers in Denmark. The two centers are located at Randers Regional Hospital and Slagelse Hospital.

SURGICAL PROCEDURE:

Included patients will undergo BLC surgery according to standardized principles. Prior to surgery, the randomization is carried out using allocation tables in REDCap, where an equal distribution of patients in the intervention group and the control group is also ensured in each center.

Intervention group: Patients in the intervention group will undergo liposuction to harvest autologous fatty cells. The patient is placed in prone position. For the liposuction, a small incision is made bilaterally in the flanks. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the lumbar region.

Adipose tissue is harvested with an equal distribution on each side of the region for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back after harvesting the fatty cells. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.

The adipose tissue is then prepared: The harvested adipose tissue is distributed equally in 10 ml syringes and centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is homogenized/microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested.

Bascom cleft lift operation is performed as described in appendix 7. Before the cleft lift incision is sutured, the fatty tissue will be systematically injected with a sharp 1.2 mm needle and cover all the wound surfaces with 0.2-0.5 ml at a time. The procedure was published as a video vignette in 2019(22). Results from the first seven patients (2020) and the first 30 patients (2022) have been published (21,23).

Patients in the control group: Control patients are given a sham, where a small incision is also made bilaterally in the lumbar region and 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and compressive dressings are applied in the same way as the intervention group.

COOPERATION PARTNERS:

Surgeries will be performed by specialists in abdominal surgery with a sub-specialty within this type of surgery in two centres: Surgical Department at Randers Regionshospital and Slagelse Hospital. I. Faurschou at Randers Regionshospital, Region Midt, has the overall responsibility for the project with Supervisor Susanne Haas as the legally responsible person. The local manager at Slagelse Hospital is P. Maine. Those responsible at each site are responsible for inclusion and informing the patients, guided and supported by I. Faurschou.

POST-OPERATIV FOLLOW-UP:

The patients will have follow ups at 4 and 12 weeks after the operation, where the healing will be clinically assessed based on endpoints by project manager I. Faurschou, blinded to the randomisation. The control takes place by telephone consultation together with answering the symptom questionnaire and pain diary sent out automatically from REDCap® as well as weekly photo documentation of healing through Pleje.net® (Dansk Telemedicin A/S), with the option of immediate physical consultation within a week in case of lack of healing. Photos will be taken using the Pleje.net app weekly in relation to hair removal by a nurse/person who handles hair removal. Patients are given a guide to Pleje.net. On Pleje.net, a user group has been set up for each site, so only project managers can see all the patients.

If there is no healing after 12 weeks, the patient will be offered further treatment in line with our normal treatment practice.

  1. STATISTICAL CONSIDERATIONS:

Sample size: In a recent study, the investigators found somewhat surprisingly that only 12% of PS patients operated with BCL surgery were fully healed after 14 days (≤ 1 defect, ≤ 5 mm, no undermining). After 12 weeks, this proportion was 72%. The investigaros expect 50% of patients to have healed after 4 weeks.

Using fatty cells in non-healing PS wounds, the investigators have a healing rate of 83% (69-96%) over a median time of 159 days. In combination with fatty cells, it is expected that 75% of patients have healed by 4 weeks. With a significance level of 5% (α) and a power of 80% (β), 66 patients will be included in each group (Fleiss with continuity correction). Assuming a dropout of 4 patients in each group, a total of 140 patients will be included.

Interim analysis: Interim analysis: Halfway through the inclusion, an interim analysis will be carried out. A Data Monitoring Committee (DMC) is set up, which will make a recommendation to the project managers on whether the study should continue as planned, be interrupted due to unintended side effects as a result of AFT, interrupted because the effect of AFT has been unequivocally established; or is interrupted because it will not be possible to see a difference if the study is continued.

  1. PATIENTS: The patients are referred to the investigators outpatient clinic and informed about the project if BCL surgery is needed (recurrent or complex disease). After reflection time, patients are included on the day of surgery, where they are randomised. After the operation, they will be followed in the outpatient 4 weeks and 12 weeks postoperatively. If there is no healing after 12 weeks, the patient will be offered further treatment in line with our normal treatment practice.
Being tested
injection of freshly collected adipose cells, Bascoms Cleft lift procedure

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • injection of freshly collected adipose cellsOther

    A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.

    Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.

    The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested.

  • Bascoms Cleft lift procedureProcedure or surgery

    The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom

Study groups in NCT05830734
Study groupRoleWhat they receive
BCL surgery with fatty cell injection armExperimentalPatients will undergo BCL surgery and additionally have to small incisions made in the lumbar region from which 80 ml of fatty cells are harvested. After harvest local anesthetics are injected bilaterally and a compression bandage applied. The fatty cells are injected into the surgical wound before closure. All wounds are lateralized and close with a suction drain removed after 3 days
Receives: Other: injection of freshly collected adipose cells; Procedure: Bascoms Cleft lift procedure
BCL surgery alone armSham comparatorPatients will undergo BCL surgery. Additionally two small incisions are made in the lumbar region, local anesthetics are injected bilaterally and a compression bandage applied. All wounds are lateralized and close with a suction drain removed after 3 days
Receives: Procedure: Bascoms Cleft lift procedure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. healing

    Healing of the pilonidal lesion (max 1 defect ≤5mm, no undermining)

    Measured: 4 weeks

  2. healing

    Healing of the pilonidal lesion (max 1 defect ≤5mm, no undermining)

    Measured: 12 weeks

Secondary outcomes (7)
  1. Symptom development

    Symptom questionnaire completed .

    Measured: pre-operatively, at 4 weeks, 12 weeks and 12 months

  2. postoperative pain

    pain diary. Daily pain measurement on a VAS score (0= no pain, 10= worst imaginable pain)

    Measured: first 14 postoperative days

  3. complications

    any early or late complications that may arise

    Measured: 12 weeks

  4. Time to healing

    the patients will be followed weekly with photos in pleje.net until healing has occured

    Measured: upto 12 months

  5. recurrence

    recurrent disease after complete healing is registered by questionnaire

    Measured: 12 months

  6. recurrence

    recurrent disease after complete healing is registered by questionnaire

    Measured: 36 months

  7. recurrence

    recurrent disease after complete healing is registered by questionnaire

    Measured: 60 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted26 Apr 2023
  2. Study start4 Jan 2023
  3. Primary completion31 Dec 2025 (estimated)
  4. Study completion31 Mar 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Double blinded randomized controlled trial
Masking
Double blind
Who is masked
Participant, Outcomes assessor
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05830734
Sponsor's protocol ID
RCTBCLAFI2022
Status last verified
Apr 2023
First submitted
6 Jan 2023
Last updated
26 Apr 2023
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: we will share individual participant data if necessary in the reviewing process

Publications

  • Sondenaa K, Andersen E, Nesvik I, Soreide JA. Patient characteristics and symptoms in chronic pilonidal sinus disease. Int J Colorectal Dis. 1995;10(1):39-42. doi: 10.1007/BF00337585.

    PubMed 7745322
  • Luedi MM, Schober P, Stauffer VK, Diekmann M, Doll D. Global Gender Differences in Pilonidal Sinus Disease: A Random-Effects Meta-Analysis. World J Surg. 2020 Nov;44(11):3702-3709. doi: 10.1007/s00268-020-05702-z. Epub 2020 Jul 17.

    PubMed 32681319
  • Enriquez-Navascues JM, Emparanza JI, Alkorta M, Placer C. Meta-analysis of randomized controlled trials comparing different techniques with primary closure for chronic pilonidal sinus. Tech Coloproctol. 2014 Oct;18(10):863-72. doi: 10.1007/s10151-014-1149-5. Epub 2014 Apr 30.

    PubMed 24845110
  • McCallum IJ, King PM, Bruce J. Healing by primary closure versus open healing after surgery for pilonidal sinus: systematic review and meta-analysis. BMJ. 2008 Apr 19;336(7649):868-71. doi: 10.1136/bmj.39517.808160.BE. Epub 2008 Apr 7.

    PubMed 18390914
  • Bascom J, Bascom T. Failed pilonidal surgery: new paradigm and new operation leading to cures. Arch Surg. 2002 Oct;137(10):1146-50; discussion 1151. doi: 10.1001/archsurg.137.10.1146.

    PubMed 12361421
  • Bascom J, Bascom T. Utility of the cleft lift procedure in refractory pilonidal disease. Am J Surg. 2007 May;193(5):606-9; discussion 609. doi: 10.1016/j.amjsurg.2007.01.008.

    PubMed 17434365
  • Guner A, Boz A, Ozkan OF, Ileli O, Kece C, Reis E. Limberg flap versus Bascom cleft lift techniques for sacrococcygeal pilonidal sinus: prospective, randomized trial. World J Surg. 2013 Sep;37(9):2074-80. doi: 10.1007/s00268-013-2111-9.

    PubMed 23732258
  • Iesalnieks I, Deimel S, Schlitt HJ. Karydakis flap for recurrent pilonidal disease. World J Surg. 2013 May;37(5):1115-20. doi: 10.1007/s00268-013-1950-8.

    PubMed 23435676
  • Nordon IM, Senapati A, Cripps NP. A prospective randomized controlled trial of simple Bascom's technique versus Bascom's cleft closure for the treatment of chronic pilonidal disease. Am J Surg. 2009 Feb;197(2):189-92. doi: 10.1016/j.amjsurg.2008.01.020. Epub 2008 Jul 17.

    PubMed 18639221
  • Theodoropoulos GE, Vlahos K, Lazaris AC, Tahteris E, Panoussopoulos D. Modified Bascom's asymmetric midgluteal cleft closure technique for recurrent pilonidal disease: early experience in a military hospital. Dis Colon Rectum. 2003 Sep;46(9):1286-91. doi: 10.1007/s10350-004-6729-4.

    PubMed 12972977
  • Iesalnieks I, Ommer A. The Management of Pilonidal Sinus. Dtsch Arztebl Int. 2019 Jan 7;116(1-2):12-21. doi: 10.3238/arztebl.2019.0012.

    PubMed 30782310
  • Mostafaei S, Norooznezhad F, Mohammadi S, Norooznezhad AH. Effectiveness of platelet-rich plasma therapy in wound healing of pilonidal sinus surgery: A comprehensive systematic review and meta-analysis. Wound Repair Regen. 2017 Nov;25(6):1002-1007. doi: 10.1111/wrr.12597. Epub 2018 Feb 7.

    PubMed 29215166
  • Mohamadi S, Norooznezhad AH, Mostafaei S, Nikbakht M, Nassiri S, Safar H, Moghaddam KA, Ghavamzadeh A, Kazemnejad A. A randomized controlled trial of effectiveness of platelet-rich plasma gel and regular dressing on wound healing time in pilonidal sinus surgery: Role of different affecting factors. Biomed J. 2019 Dec;42(6):403-410. doi: 10.1016/j.bj.2019.05.002. Epub 2019 Dec 10.

    PubMed 31948604
  • Cabalzar-Wondberg D, Turina M, Biedermann L, Rogler G, Schreiner P. Allogeneic expanded adipose-derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. Colorectal Dis. 2021 Jun;23(6):1444-1450. doi: 10.1111/codi.15587. Epub 2021 Mar 5.

    PubMed 33595166
  • Garcia-Arranz M, Herreros MD, Gonzalez-Gomez C, de la Quintana P, Guadalajara H, Georgiev-Hristov T, Trebol J, Garcia-Olmo D. Treatment of Crohn's-Related Rectovaginal Fistula With Allogeneic Expanded-Adipose Derived Stem Cells: A Phase I-IIa Clinical Trial. Stem Cells Transl Med. 2016 Nov;5(11):1441-1446. doi: 10.5966/sctm.2015-0356. Epub 2016 Jul 13.

    PubMed 27412883

Questions about this trial

What is this clinical trial studying?

A study testing injection of freshly collected adipose cells and Bascoms Cleft lift procedure in people with Pilonidal Disease, run by University of Aarhus at 1 site in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 26 Apr 2023. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ida Faurschou, MD (28707759, idafau@rm.dk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

healing (time frame: 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05830734, which also lists 23 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 26 Apr 2023.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in